Anti-CD30 antibody-based therapy

被引：22

作者：

Koon, HB ^{[1
]}

Junghans, RP ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA

来源：

CURRENT OPINION IN ONCOLOGY | 2000年 / 12卷 / 06期

关键词：

D O I：

10.1097/00001622-200011000-00012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The increased expression of CD30 on some neoplasms versus its limited expression on normal tissue makes it an excellent target for antibody-based therapy. Recent studies have shown that anti-CD30 antibodies may serve as signaling molecules as well as mediators of interactions with the immune system. Unmodified anti-CD30 antibodies as well as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconjugates have been examined in preclinical and clinical studies. The data show that anti-CD30-based therapies are promising new treatment modalities for CD30+ neoplasms. Curr Opin Oncol 2000, 12:588-593 (C) 2000 Lippincott Williams & Wilkins, Inc.

引用

页码：588 / 593

页数：6

共 44 条

[1] Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice [J].

Amakawa, R ;

Hakem, A ;

Kundig, TM ;

Matsuyama, T ;

Simard, JJL ;

Timms, E ;

Wakeham, A ;

Mittruecker, HW ;

Griesser, H ;

Takimoto, H ;

Schmits, R ;

Shahinian, A ;

Ohashi, PS ;

Penninger, JM ;

Mak, TW .

CELL, 1996, 84 (04) :551-562

[2] A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors [J].

Arndt, MAE ;

Krauss, J ;

Kipriyanov, SM ;

Pfreundschuh, M ;

Little, M .

BLOOD, 1999, 94 (08) :2562-2568

[3]

Barth S, 2000, BLOOD, V95, P3909

[4]

Barth S, 1999, CYTOKINES CELL MOL T, V5, P69

[5]

Bauer S, 1999, CANCER RES, V59, P1961

[6]

BOLOGNESI A, 1995, CANCER IMMUNOL IMMUN, V40, P109, DOI 10.1007/s002620050151

[7]

DEBRUIN PC, 1995, LEUKEMIA, V9, P1620

[8]

Dürkop H, 2000, J PATHOL, V190, P613

[9]

ENGERT A, 1990, CANCER RES, V50, P84

[10]

ENGERT A, 1990, CANCER RES, V50, P2929

← 1 2 3 4 5 →